News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Peter MacCallum Cancer Centre And Affymetrix (Santa Clara, California) (AFFX) Initiate Five-Year Translational Research Collaboration



9/27/2006 11:12:23 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip® microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES